908 Devices reported record third-quarter revenue of $19.0 million, a 35% increase year-over-year, driven by strong demand for its FTIR portfolio and the addition of NIRLab revenue. The company achieved a record 308 device shipments in the quarter and raised the low end of its full-year 2026 revenue guidance to a range of $68.5 million to $70.0 million.
Term
Q3 2026
“We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record.”
Kevin J. Knopp, CEO and Co-founder
“Our proven platforms are winning orders across the globe as customers accelerate efforts to modernize their detection capabilities and stay ahead of an evolving threat landscape.”
Upstream Bio reported third quarter 2026 financial results, ending the period with $207.4 million in cash and short-term investments. The company is preparing to initiate Phase 3 trials for its lead candidate verekitug in severe asthma and CRSwNP in the first quarter of 2027. Research and development expenses increased to $36.6 million as the company advances its clinical programs and expands its personnel.
Term
Q3 2026
“Our team is focused on the timely execution of startup activities for verekitug’s Phase 3 trials in severe asthma and CRSwNP. Preparations for the planned initiation of these trials in the first quarter of 2027 are well underway, with key clinical, regulatory, and manufacturing milestones now having been achieved.”
Rand Sutherland, MD, Chief Executive Officer of Upstream Bio
“As we look ahead, we remain focused on advancing verekitug in diseases with significant remaining unmet medical need, where we believe its compelling efficacy profile and convenient quarterly at-home dosing have the opportunity to meaningfully redefine treatment expectations and establish a new standard of care.”
Rand Sutherland, MD, Chief Executive Officer of Upstream Bio
Olema Pharmaceuticals reported a net loss of $73.6 million for the third quarter of 2026, driven by increased clinical trial enrollment costs. The company ended the period with $413.8 million in cash and remains on track to report pivotal Phase 3 OPERA-01 data in the first quarter of 2027.
Term
Q3 2026
“As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine therapy in second- and third-line metastatic breast cancer.”
Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer
“We believe that palazestrant, in combination with ribociclib, is well positioned to become the new standard of care in this setting. With its dual mechanism of action as a complete estrogen receptor antagonist and selective estrogen receptor degrader, optimal pharmacokinetic properties, encouraging clinical profile demonstrated to date, and potential for use both as a monotherapy and in combination with other agents, we believe palazestrant is uniquely positioned to transform the metastatic breast cancer treatment paradigm.”
Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer
Humacyte reported Q3 2026 financial results, highlighted by a 151% sequential increase in Symvess revenue to $1.0 million. The company remains on track to file a supplemental Biologics License Application (sBLA) for its ATEV in dialysis access with the FDA in November 2026.
Term
Q3 2026
“During our third quarter, we continued the transformation of our Symvess commercial program in vascular injury repair, doubling revenue over our second quarter and significantly increasing the number of hospitals ordering Symvess.”
Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte
“Execution of our revamped commercial program for Symvess generated significant momentum during the third quarter. Symvess sales revenue for the third quarter was $1.0 million, more than double our results for the second quarter, and achieved the goal we set for the period.”
Jim Mercadante, Chief Commercial Officer of Humacyte
Protalix BioTherapeutics reported a significant turnaround for the nine months ended September 30, 2026, with net income of $26.1 million compared to a net loss of $1.1 million in the prior year period. This growth was driven by a substantial increase in total revenue to $75.6 million, primarily due to a surge in license and R&D services revenue.
Ovid Therapeutics reported third quarter 2026 financial results, ending the period with $161.4 million in cash and marketable securities. The company highlighted clinical progress for OV329 in focal epilepsy and the initiation of a Phase 1 study for OV4071, with a projected financial runway extending into 2029.
Term
Q3 2026
“The third quarter was focused on execution toward multiple, near-term clinical milestones across our pipeline. We anticipate findings from two high potential programs in early 2027, which may respectively demonstrate the broad potential of KCC2 direct activation and the anticonvulsant profile of OV329, a next-generation GABA-AT inhibitor.”
Meg Alexander, President and Chief Executive Officer
D-Wave Quantum reported Q3 2026 revenue of $4.5 million, a 21% year-over-year increase, driven by growing commercial interest in its dual-platform quantum approach. The company highlighted a 611% surge in year-to-date bookings to $37.4 million and the execution of a definitive agreement for up to $100 million in U.S. CHIPS Act funding to support next-generation system development.
Term
Q3 2026
“From Seoul to Como to Washington, we are seeing growing interest in D-Wave’s differentiated dual-platform approach and a determination to put our quantum computing technology to work today. Our triple-digit increase in year-to-date bookings and robust pipeline reinforce our confidence in the opportunity ahead. We are expanding our commercial reach and executing on both our annealing and gate-model roadmaps with a clear objective: to lead this industry in technical and scientific innovation, measurable customer value and growth.”
Opus Genetics reported financial results for the third quarter of 2026, highlighting a cash runway extending into 2029. The company achieved several clinical milestones, including full enrollment of its OPGx-LCA5 Phase 3 trial and FDA clearance of the IND for OPGx-RDH12. Additionally, the FDA approval of RYZUMVI for presbyopia triggered a regulatory milestone payment to the company.
Term
Q3 2026
“The last several months have marked a period of tremendous advancement for our leading gene therapy programs. Positive Cohort 1 data from our Phase 1/2 trial of OPGx-BEST1 provide important evidence of its potential to improve both visual function and retinal structure in patients with BEST1-related retinal disease.”
George Magrath, M.D., Chief Executive Officer of Opus Genetics
“The FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia marks the second FDA-approved indication for RYZUMVI®, demonstrating the capabilities of our clinical and regulatory teams. With our cash runway into 2029, we remain focused on bringing potentially transformative gene therapies to patients with rare inherited retinal diseases.”
George Magrath, M.D., Chief Executive Officer of Opus Genetics
Chicago Atlantic Real Estate Finance Financial Results
Chicago Atlantic Real Estate Finance reported third quarter 2026 financial results, including net income of $6.4 million and distributable earnings of $0.49 per diluted share. The company's total loan principal outstanding grew to $527.7 million, supported by $88.0 million in principal advances during the quarter. Management highlighted the strategic Koach transaction and disciplined underwriting despite a challenging macroeconomic environment.
Term
Q3 2026
“Chicago Atlantic delivered distributable earnings of $0.49 per diluted weighted average share for the third quarter of 2026, despite a challenging macroeconomic environment and heightened uncertainty across both the regulatory landscape and the mortgage REIT sector.”
Peter Sack, Co-Chief Executive Officer
“We believe the deliberate, strategic decisions we have made, such as the Koach transaction in the third quarter, position the Company for long-term success.”
For the nine months ended September 30, 2026, Chicago Atlantic Real Estate Finance reported net income of $18.7 million, a decrease from $27.9 million in the prior year period, primarily driven by a significant increase in the provision for current expected credit losses. Total assets grew to $468.2 million, supported by an increase in loans held for investment and the issuance of common stock in exchange for notes.
Liquidia Corporation reported Q3 2026 financial results, highlighted by $222.7 million in YUTREPIA net product sales, a 31% increase over the prior quarter. The company recorded a net loss of $236.3 million, which was primarily driven by a $389.7 million litigation settlement charge to resolve all outstanding disputes with United Therapeutics. Liquidia ended the quarter with $396.1 million in cash and cash equivalents.
Term
Q3 2026
“Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient’s therapy. That affinity and broad adoption have proven durable and our business continues to grow in parallel. With the litigation now fully resolved, and YUTREPIA’S commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin.”
Dr. Roger Jeffs, Liquidia’s Chief Executive Officer
Janus International Group reported third quarter 2026 revenues of $213.1 million, a 2.8% decrease year-over-year, and a net loss of $13.3 million. The company updated its full-year 2026 revenue guidance to a range of $855 million to $865 million and noted it repurchased 5.0 million shares during the quarter for $25.3 million.
Term
Q3 2026
“Market conditions remained dynamic during the third quarter, with activity levels softer than anticipated. While we continue to believe the long-term fundamentals supporting our business remain intact, we are taking actions to align our operating structure with current demand, improve efficiency, and strengthen the business.”
Harvard Bioscience reported Q3 2026 revenue of $22.2 million, an 8% increase year-over-year, driven by strong demand from CROs and customers in China. The company reported a net loss of $2.6 million for the quarter and reaffirmed its full-year 2026 revenue growth guidance of 3% to 5%.
Term
Q3 2026
“We delivered our second consecutive quarter of strong year over year growth with an 8% topline increase in the third quarter. We saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products.”
Cellectar Biosciences reported a net loss of $20.6 million for the nine months ended September 30, 2026, as it continues to invest in its phospholipid drug conjugate platform. The company significantly improved its cash position to $24.6 million through the issuance of common stock and warrants, though management notes a continued dependence on outside capital to fund operations.
IHS Holding Ltd is navigating significant macroeconomic risks, including Nigerian Naira volatility and potential impacts from a merger agreement with MTN Group Limited. The company continues to manage its debt profile through various senior notes while executing its 'Carbon Reduction Roadmap' to reduce emissions intensity by 50% by 2030.
Protalix BioTherapeutics reported Q3 2026 financial results with total year-to-date revenues reaching $75.6 million, a significant increase from $43.6 million in the prior year. The company reported quarterly net income of $4.0 million and reaffirmed its full-year 2026 revenue guidance of $78.0 million to $83.0 million. Management highlighted the ongoing Phase 2 RELEASE study for PRX-115 in uncontrolled gout, with top-line results expected in the second half of 2027.
Term
Q3 2026
“We concluded the first nine months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial strength which supports our ability to execute our strategy and advance our key priorities.”
Dror Bashan, President and Chief Executive Officer
“We end the quarter with cash and deposits of $48.5 million, a position of strength that enables us to continue advancing PRX-115 for uncontrolled gout. Uncontrolled gout is a disease with low quality of life and high unmet need and represents a blockbuster uricase market opportunity.”
Dror Bashan, President and Chief Executive Officer
WhiteFiber, Inc. reported a significant revenue increase to $74.8 million for the nine months ended September 30, 2026, driven by growth in cloud and colocation services. However, the company incurred a substantial net loss of $128.5 million, primarily due to an $80.8 million induced conversion expense related to its convertible notes.
Sally Beauty Holdings reported fourth quarter and full year 2026 results, featuring a 0.6% increase in Q4 consolidated net sales to $953 million and 22% growth in GAAP diluted EPS. The company generated $323 million in full-year operating cash flow and provided fiscal 2027 guidance in line with its long-term financial algorithm.
Term
Q4 2026
“We finished fiscal 2026 with positive momentum, delivering fourth quarter sales, operating earnings and double-digit adjusted EPS growth. Throughout the year, we strengthened our business through disciplined execution, new customer growth, digital and omnichannel expansion, product innovation, and continued advancement of our long-term growth agenda.”
Denise Paulonis, president and chief executive officer
Ampco-Pittsburgh reported net income attributable to the corporation of $0.46 million for the quarter ended September 30, 2026, a significant improvement from a net loss of $2.21 million in the prior year period. While total net sales for the nine-month period slightly decreased to $322.9 million, income from operations rose to $12.25 million compared to $1.90 million in 2025, driven by lower depreciation and the absence of significant prior-year severance charges.
Liquidia Corp is a non-accelerated filer focused on the commercialization of YUTREPIA and the development of L606 for pulmonary hypertension. As of October 28, 2026, the company reported 90,106,442 shares of common stock outstanding and is navigating ongoing legal settlements and regulatory filings with the FDA.
Keenova Therapeutics reported Q3 2026 net sales of $550 million, driven by strong performance from core brands Acthar Gel and XIAFLEX. The company raised its full-year guidance for net sales and Adjusted EBITDA based on higher growth expectations for XIAFLEX and continued demand for Acthar Gel.
Term
Q3 2026
“On this day last year, Keenova introduced itself as a new company with a new identity and a bright future. Since that day, we have made significant strategic, commercial, operational, and clinical progress toward fulfilling our goal of becoming a pure-play branded therapeutics company. Our third-quarter 2026 results further demonstrate the consistent progress we are making against that goal.”
Siggi Olafsson, Board Chair and Chief Executive Officer
“In the quarter our core brands, Acthar Gel and XIAFLEX, contributed better-than-expected performance, driven primarily by increased demand and improved operational execution. As a result, we are reiterating our full-year net sales growth outlook for Acthar Gel of 20% to 22% and now expect XIAFLEX net sales to grow 10% to 11% year over year.”
Siggi Olafsson, Board Chair and Chief Executive Officer
TransDigm Group reported fiscal Q4 2026 net sales of $2.99 billion, a 23% increase year-over-year, driven by 14% organic growth. While net income decreased 4% to $586 million due to higher interest and tax expenses, Adjusted EPS rose 15% to $12.44. The company also highlighted the completion of its $1.07 billion acquisition of Prince & Izant and the repurchase of $943 million in common stock during the quarter.
Venture Global reported record Q3 2026 results with revenue of $4.8 billion and net income of $2.5 billion, driven by high LNG production and the commencement of commercial operations at Plaquemines Phase 1. The company raised its full-year 2026 guidance for volume and Adjusted EBITDA and announced plans to leverage its power infrastructure for a potential off-grid AI utility business for data centers.
Term
Q3 2026
“Venture Global had an exceptional third quarter, with record sales and earnings, enabled by our team's best-in-class execution and LNG production at the high end of our anticipated range. We are proud to have commenced commercial operations at Plaquemines Phase 1 on October 31st and begun delivering on our long-term contracts at one of the fastest rates for a greenfield LNG project of this scale.”
Mike Sabel, Venture Global CEO
“We are also excited about a potential new, additive line of business for the Company: expanding our existing and proven capabilities building and operating an island-mode power and infrastructure network to be able to offer an off-grid AI utility to support data centers.”
Black Diamond Therapeutics reported total assets of $115.6 million as of September 30, 2026, a decrease from $143.0 million at year-end 2025. The company is focused on advancing its lead candidate silevertinib toward Phase 3 trials and managing its partnership with Servier Pharmaceuticals for BDTX-4933.
Meridian Holdings Inc. reported a significant net loss of $14.7 million for the quarter ended September 30, 2026, compared to a net income of $0.4 million in the prior year, primarily driven by $11.5 million in impairment charges for goodwill and intangible assets. While nine-month revenues grew to $146.3 million from $133.3 million, the company's total equity declined from $48.3 million at the end of 2025 to $36.7 million as of September 30, 2026.
Sono Group N.V. reported its first full quarter as a Bitcoin treasury company, swinging to a net income of $0.6 million for Q3 2026. The results were driven by $0.7 million in digital asset treasury income and non-cash fair-value gains on its Bitcoin holdings. The company also highlighted its pending redomiciliation to Delaware and a non-binding letter of intent for a business combination with Sports One.
Black Diamond Therapeutics reported Q3 2026 financial results and updated Phase 2 data for silevertinib in frontline NSCLC, showing an 86% CNS-ORR in patients with brain metastases. The company received FDA feedback supporting a pivotal Phase 3 trial design with potential for accelerated approval. Current cash reserves of $102.0 million are expected to fund operations into the second half of 2028.
Term
Q3 2026
“Our recent end of Phase 2 meeting with the FDA was highly collaborative, and we believe the feedback we received supports a clear path to potential accelerated and full approval for silevertinib in frontline NSCLC patients with EGFR non-classical mutations. This trial design offers a differentiated path to potential accelerated approval in EGFR-NCM patients, who represent about 25% of the frontline EGFR mutant patient population.”
Mark Velleca, M.D., Ph.D., President and Chief Executive Officer
“We believe that silevertinib’s ability to significantly delay CNS progression is the key driver of the durable clinical benefit we are seeing in patients both with and without baseline brain metastases and is the foundation of the pivotal program design in 1L NSCLC.”
Sergey Yurasov, M.D., Ph.D., Chief Medical Officer
Fervo Energy Company completed its IPO in May 2026, raising approximately $2.04 billion in net proceeds. For the nine months ended September 30, 2026, the company reported a net loss of $76.1 million on revenues of $290 thousand, while significantly increasing its property, plant, and equipment assets to $487 million through its consolidated VIEs.
Ampco-Pittsburgh reported Q3 2026 net sales of $111.7 million, a 3% increase year-over-year, driven by strong demand in the Air and Liquid Processing segment. The company returned to profitability with net income of $0.5 million compared to a net loss in the prior year, supported by strategic facility ramp-ups in Sweden and improved manufacturing efficiency. Backlog grew significantly to $379.5 million, reflecting increased customer order activity.
Term
Q3 2026
“Our third quarter reflects the progress we have made in building a stronger, more profitable Ampco-Pittsburgh. Even in a seasonally slower quarter, both segments improved profitability compared to the prior year period, we generated strong cash flow through disciplined working capital management, and we used it to pay down debt and strengthen our financial flexibility.”
Kustom Entertainment, Inc. reported a significant increase in total revenue to $11.3 million for the nine months ended September 30, 2026, compared to $6.8 million in 2025, driven by growth in service revenue. Despite this, the company recorded a net loss of $8.1 million for the period, impacted by a $6.4 million operating loss and a $1.3 million loss from other expenses.